Clinical Trials Logo

MET Gene Alterations clinical trials

View clinical trials related to MET Gene Alterations.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03993873 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

SHIELD-1
Start date: September 21, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)